Clinical trial
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic…
NCT00044486 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00044486 |
|---|---|
| Title | Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) |
| Official title | A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Myelocytic, Acute, Myelodysplastic Syndromes, Neutropenia |
| Intervention type | Drug |
| Interventions | Posaconazole oral suspension |
| Enrollment | 602 |
| Start date | Jul 1, 2002 |
| Primary completion | Dec 1, 2004 |
| Completion | Apr 1, 2005 |
| First posted | Sep 4, 2002 |
| Last update posted | Mar 10, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: